[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
An antiviral drug containing remdesivir, developed by Richter Gedeon Nyrt., Is the most effective drug known to date against COVID infection.
The clinical trial of the preparation has been approved by the National Institute of Pharmacy and Food Health (OGYÉI), so the drug will be used in several Hungarian health institutions, such as the University of Szeged.
In the first round, four higher education institutions with medical schools – the University of Szeged, Semmelweis University, the University of Debrecen and the University of Pécs – as well as the South Pest Center Hospital, the Korányi National Institute of Pulmonology and the New St. John’s Hospital will use the product: for it to be widely used in Hungary, it still has to go through clinical phases. meIn view of this, the drug can be administered to patients treated at the above institutions who are 12 years of age or older and have a moderate to severe course of viral infection. The drug to be infused should be used as a cure, the course lasts 5-10 days, it can only be administered in health care institutions, it will not be marketed to the general public.
A previous article in the Index shows that patients seen in the hospital also cannot request the study separately. Those who are admitted to these institutions and are eligible to receive this drug will start treatment after consent, the active ingredients will be given to all, there is no control group. It is used in patients who Covid infection confirmed by PCR or without test but clear symptoms or his condition is already so severe that he needs additional oxygen treatment.
Research on Covid control has shown it to be extremely effective against COVID infection, as international research
it can reduce the risk of death by up to 50 percent, which is a very significant result.
Gedeon Richter Plc., The ITM and EMMI backbone institutions, the Clinical Pharmacology Ethics Committee of the Operating Staff, OGYÉI and ETT participated in the development of the drug and its delivery to patients. The main research coordinator is the Hungarian Clinical Research Infrastructure Network (HECRIN).
The Index also reported that Richter had made sufficient preparations to treat 3,000 patients, which he turned over to the government. It is not yet clear why this number was only produced when 1,500 patients are hospitalized, and that number is steadily growing.
Cover image: Getty Images
[ad_2]
